Doxepin News
Clinical Data on Somaxon Pharmaceuticals' Product Candidate for the Treatment of Insomnia Presented at American Psychiatric Association Annual Meeting
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of...
Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and...
Low Dose Doxepin is Safe and Effective in Chronic Primary Insomnia Patients
Chronic insomnia is prevalent in almost 10% of the adult population, and primary insomnia has been estimated to occur in 25% of all chronic insomnia patients. Although sedative-hypnotics, such as benzodiazepines, are the mainstay...
Somaxon Pharmaceuticals Provides Update On SILENOR(TM) Development Program For The Treatment Of Insomnia
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today is providing information on its development program for SILENOR(TM) (doxepin HCl), its lead drug candidate currently in Phase 3 clinical trials for the treatment of insomnia.
Going off depression medications risks relapse
Patients with diabetes (who need insulin chronically) and patients with hypertension (who take anti-hypertensive drugs on a regular basis) are in a similar situation. Their medications, such as antidepressants, do not merely mask...